U.S. patent application number 12/573022 was filed with the patent office on 2010-01-28 for extended release oral dosage composition.
This patent application is currently assigned to Schering Corporation. Invention is credited to Wing-Kee Philip Cho.
Application Number | 20100021542 12/573022 |
Document ID | / |
Family ID | 22629073 |
Filed Date | 2010-01-28 |
United States Patent
Application |
20100021542 |
Kind Code |
A1 |
Cho; Wing-Kee Philip |
January 28, 2010 |
EXTENDED RELEASE ORAL DOSAGE COMPOSITION
Abstract
A bilayer solid composition comprising (a) an immediate release
first layer comprising an anti-allergic effective amount of
desloratadine and at least one pharmaceutically acceptable
excipient and (b) a sustained release second layer comprising an
effective amount of a nasal decongestant, e.g. pseudoephedrine
sulfate and a pharmaceutically acceptable sustained release agent
wherein the composition contains less than about 2% of
desloratadine decomposition products is disclosed. A solid
composition comprising an anti-allergic effective amount of
desloratadine and at least one, and preferably two pharmaceutically
acceptable antioxidants is also disclosed.
Inventors: |
Cho; Wing-Kee Philip;
(Princeton, NJ) |
Correspondence
Address: |
COVINGTON & BURLING, LLP;ATTN: PATENT DOCKETING
1201 PENNSYLVANIA AVENUE, N.W.
WASHINGTON
DC
20004-2401
US
|
Assignee: |
Schering Corporation
Kenilworth
NJ
|
Family ID: |
22629073 |
Appl. No.: |
12/573022 |
Filed: |
October 2, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10699987 |
Nov 3, 2003 |
7618649 |
|
|
12573022 |
|
|
|
|
10175480 |
Jun 19, 2002 |
6709676 |
|
|
10699987 |
|
|
|
|
PCT/US00/34404 |
Dec 19, 2000 |
|
|
|
10175480 |
|
|
|
|
60172752 |
Dec 20, 1999 |
|
|
|
Current U.S.
Class: |
424/472 ;
514/290 |
Current CPC
Class: |
A61K 31/4545 20130101;
A61P 37/08 20180101; A61P 27/14 20180101; A61K 47/12 20130101; A61P
11/00 20180101; A61K 31/137 20130101; A61K 9/2013 20130101; A61P
37/00 20180101; A61K 47/183 20130101; A61P 43/00 20180101; A61K
47/02 20130101; A61P 11/02 20180101; A61P 29/00 20180101; A61K
9/209 20130101; A61K 31/473 20130101; A61K 9/2009 20130101; A61P
39/00 20180101; A61K 31/445 20130101; A61K 31/445 20130101; A61K
31/135 20130101; A61K 31/137 20130101; A61K 2300/00 20130101; A61K
31/445 20130101; A61K 2300/00 20130101; A61K 31/473 20130101; A61K
2300/00 20130101 |
Class at
Publication: |
424/472 ;
514/290 |
International
Class: |
A61K 9/24 20060101
A61K009/24; A61K 31/435 20060101 A61K031/435 |
Claims
1-41. (canceled)
42. A solid composition comprising: (1) an immediate release layer
comprising an anti-allergic effective amount of desloratadine and a
desloratadine-protective amount of two pharmaceutically acceptable
antioxidants; and (2) a sustained release layer comprising an
effective amount of pseudoephedrine or a pharmaceutically
acceptable salt thereof and a pharmaceutically acceptable sustained
release agent; wherein the total amount of desloratadine
degradation products in the solid composition is less than or equal
to about 2% by weight.
43. The solid composition of claim 42 wherein the two
pharmaceutically acceptable antioxidants are edetate disodium and
citric acid.
44. A solid composition comprising: (1) an immediate release first
layer comprising an anti-allergic effective amount of desloratadine
and at least one pharmaceutically acceptable antioxidant; and (2) a
sustained release second layer comprising an effective amount of
pseudoephedrine or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable sustained release agent; wherein the
total amount of desloratadine degradation products in the solid
composition is less than or equal to about 2% by weight.
45. A solid composition comprising: (1) an immediate release first
layer comprising about 2.5 mg of desloratadine and a
desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant; (2) a sustained release second layer
comprising about 120 mg of pseudoephedrine or a pharmaceutically
acceptable salt thereof; and (3) a pharmaceutically acceptable
excipient.
46. The solid composition of claim 45 wherein the total amount of
desloratadine degradation products is less than or equal to about
2% by weight.
47. The solid composition of claim 45 wherein a
desloratadine-protective amount of a pharmaceutically acceptable
binder is present in the sustained release second layer.
48. The solid composition of claim 45 wherein at least about 80% of
the desloratadine dissolves in a 0.1N HCl solution at 37.degree. C.
in about 45 minutes.
49. The solid composition comprising a first and a second layer
wherein the first layer is an immediate release layer comprising:
TABLE-US-00021 INGREDIENT mg/composition Desloratadine, micronized
5.0 Corn Starch 36.0 Microcrystalline Cellulose 140.7 Edetate
Disodium 10.0 Citric Acid 2.0 Talc 6.0 Dye 0.30 TOTAL 200.00
and wherein the second layer is a sustained release layer
comprising: TABLE-US-00022 INGREDIENT mg/composition
Pseudoephedrine Sulfate 120.0 Hydroxypropyl Methylcellulose 2208,
100,000 cps 105.0 Microcrystalline Cellulose 103.5 Hydroxypropyl
Methylcellulose 2910 10.5 Edetate Disodium 3.5 Silicon Dioxide 5.0
Magnesium Stearate (Non-Bovine) 2.5 TOTAL 350.0 TOTAL Tablet Weight
550.0
wherein the total amount of desloratadine degradation products in
the solid composition is less than or equal to about 2% by
weight.
50. A solid composition comprising a first layer and a second
layer, wherein the first layer is an immediate release first layer
comprising: TABLE-US-00023 INGREDIENT mg/composition Desloratadine,
micronized 2.5 Corn Starch 18.0 Microcrystalline Cellulose 71.22
Edetate Disodium 5.0 Citric Acid 1.0 Talc 3.0 Dye 0.28 TOTAL
100.00
and wherein the second layer is a sustained release layer
comprising: TABLE-US-00024 INGREDIENT mg/composition
Pseudoephedrine Sulfate 120.0 Hydroxypropyl Methylcellulose 2208
105.0 Microcrystalline cellulose 103.5 Edetate Disodium 3.5
Hydroxypropyl Methylcellulose 2910 10.5 Silicon Dioxide 5.0
Magnesium stearate 2.5 TOTAL 350.0
and wherein total amount of desloratadine degradation products in
the solid composition is less than or equal to about 2% by
weight.
51. The solid composition of claim 50 wherein at least about 80% of
the desloratadine dissolves in a 0.1N HCl solution at 37.degree. C.
in about 45 minutes.
52. A method of treating allergic or inflammatory conditions of the
upper and lower airway passages and skin which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 42.
53. A method of treating the signs and symptoms of nasal congestion
associated with allergic and inflammatory conditions of the upper
or lower airway passages and skin which comprises administering to
a patient in need of such treating an effective amount of the solid
composition of claim 42.
54. A method of treating the signs and symptoms of nasal congestion
associated with allergic or inflammatory conditions of the upper
and lower airway passages and skin which comprises administering to
a patient in need of such treating an effective amount of the solid
composition of claim 44.
55. A method of treating the signs and symptoms of nasal congestion
associated with allergic or inflammatory conditions of the upper
and lower airway passages and skin which comprises administering to
a patient in need of such treating an effective amount of the solid
composition of claim 45.
56. A method of treating the signs and symptoms of nasal congestion
associated with allergic or inflammatory conditions of the upper
and lower airway passages and skin which comprises administering to
a patient in need of such treating an effective amount of the solid
composition of claim 50.
57. A method of treating the signs and symptoms of urticaria which
comprises administering to a patient in need of such treating an
effective amount of the solid composition of claim 42.
58. A method of treating the signs and symptoms of urticaria which
comprises administering to a patient in need of such treating an
effective amount of the solid composition of claim 44.
59. A method of treating the signs and symptoms of urticaria which
comprises administering to a patient in need of such treating an
effective amount of the solid composition of claim 45.
60. A method of treating the signs and symptoms of urticaria which
comprises administering to a patient in need of such treating an
effective amount of the solid composition of claim 49.
61. A method of treating the signs and symptoms of urticaria which
comprises administering to a patient in need of such treating an
effective amount of the solid composition of claim 50.
62. A method of treating the nasal and non-nasal symptoms of
perennial or seasonal allergic rhinitis which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 42.
63. A method of treating the nasal and non-nasal symptoms of
perennial or seasonal allergic rhinitis which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 44.
64. A method of treating the nasal and non-nasal symptoms of
perennial or seasonal allergic rhinitis which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 45.
65. A method of treating the nasal and non-nasal symptoms of
perennial or seasonal allergic rhinitis which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 49.
66. A method of treating the nasal and non-nasal symptoms of
perennial or seasonal allergic rhinitis which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 50.
67. A method of treating allergic or inflammatory conditions of the
upper and lower airway passages and skin which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 44.
68. A method of treating allergic or inflammatory conditions of the
upper and lower airway passages and skin which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 45.
69. A method of treating allergic or inflammatory conditions of the
upper and lower airway passages and skin which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 49.
70. A method of treating allergic or inflammatory conditions of the
upper and lower airway passages and skin which comprises
administering to a patient in need of such treating an effective
amount of the solid composition of claim 50.
71. A method of treating the signs and symptoms of nasal congestion
associated with allergic and inflammatory conditions of the upper
or lower airway passages and skin which comprises administering to
a patient in need of such treating an effective amount of the solid
composition of claim 49.
Description
BACKGROUND OF THE INVENTION
[0001] This invention relates to oral dosage compositions,
including a bilayer sustained release oral dosage composition
containing a nasal decongestant, e.g., pseudoephedrine in one layer
and the non-sedating antihistamine, desloratadine in a second layer
and having less than about 2% of desloratadine degradation products
in the compositions. The oral dosage compositions of this invention
are useful for treating patients showing the signs and symptoms
associated with allergic and/or inflammatory conditions such as the
common cold, as well as signs and symptoms associated with allergic
and/or inflammatory conditions of the skin such as dermatitis, and
airway passages such as the upper respiratory disease conditions,
perennial allergic rhinitis, seasonal allergic rhinitis and nasal
congestion, allergic asthma, and nasal congestion.
[0002] Desloratadine, also called descarbethoxyloratadine, is
disclosed in U.S. Pat. No. 4,659,716 as a non-sedating
antihistamine useful as an anti-allergy agent. U.S. Pat. No.
5,595,997 discloses methods and compositions for treating seasonal
allergic rhinitis symptoms using desloratadine.
[0003] U.S. Pat. Nos. 4,990,535 and 5,100,675 disclose a
twice-a-day sustained release coated tablet wherein the tablet
coating comprises descarbethoxyloratadine and a hydrophilic polymer
and polyethylene glycol, and the tablet core comprises
acetaminophen, pseudoephedrine or a salt thereof, a swellable
hydrophilic polymer and pharmaceutically acceptable excipients.
[0004] U.S. Pat. No. 5,314,697 discloses an extended release tablet
containing matrix core comprising pseudoephedrine sulfate and a
coating comprising loratadine.
[0005] None of the prior art discloses the solid oral dosage
compositions of this invention.
[0006] The successful development of a formulation of a
desloratadine-pseudoephedrine twice-a-day and once-a-day products
would be desirable, but would require (1) achieving a release rate
profile for pseudoephedrine component over an extended period of
about twelve hours or twenty four hours, respectively, while
maintaining the safety and effectiveness of desloratadine, and (2)
minimizing impurity formation due to the interaction between
desloratadine and excipients in the pseudoephedrine layer that are
incompatible with desloratadine.
[0007] It would be desirable for increased patient compliance to
have a stable, extended release desloratadine-pseudoephedrine
product substantially free of desloratadine impurities and
additional polymorphic forms that is effective and safe when used
on a twice-a-day or once-a-day basis for the treatment, management
and/or mitigation of the signs and symptoms associated with the
common cold, as well as allergic and/or inflammatory conditions of
the skin or upper and lower airway passages such as seasonal and
perennial allergic rhinitis and nasal congestion.
SUMMARY OF THE INVENTION
[0008] We have found that desloratadine discolors and decomposes in
the presence of excipients disclosed in the prior art. We have
discovered that these problems are substantially solved by (a)
bilayer solid compositions of the present invention wherein
immediate release layer contains desloratadine combined with a
pharmaceutically acceptable carrier medium comprising a
desloratadine protective amount of a pharmaceutically acceptable
basic salt, and wherein the use of an acidic excipient in the
immediate release layer is substantially avoided or (b) bilayer
solid compositions of the present invention wherein a
desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant is present in at least one layer, and
preferably, wherein two of said antioxidants are present in
desloratadine-containing immediate release layer.
[0009] Thus, this invention provides a bilayer solid composition
comprising (a) an immediate release first layer comprising an
anti-allergic effective amount of desloratadine and at least one
pharmaceutically acceptable excipient and (b) a sustained release
second layer comprising an effective amount of a nasal decongestant
and a pharmaceutically acceptable sustained release agent wherein
the total amount of desloratadine decomposition products in the
composition is less than, or equal to, about 2% by weight.
[0010] This invention also provides a bilayer solid composition
comprising (1) an immediate release first layer comprising an
anti-allergic effective amount of desloratadine and a
desloratadine-protective amount of a pharmaceutically acceptable
water insoluble basic calcium, magnesium or aluminum salt, or of a
desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant; and (2) a sustained release second layer
comprising an effective amount of pseudoephedrine or a salt
thereof, and a pharmaceutically acceptable sustained release agent,
and optionally a desloratadine-protective amount of a
pharmaceutically acceptable antioxidant.
[0011] Thus, in one preferred embodiment, this invention provides a
bilayer solid composition comprising (1) an immediate release first
layer comprising an anti-allergic effective amount of desloratadine
and desloratadine-protective amount of a pharmaceutically
acceptable water insoluble basic calcium, magnesium or aluminum
salt, and (2) a sustained release second layer comprising an
effective amount of pseudoephedrine or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable
sustained release agent. The immediate release layer is
substantially free of, i.e., contains less than about 1%,
preferably, less than about 0.5%, and more preferably less than
about 0.25% of acidic excipients.
[0012] The total amount of desloratadine decomposition products in
the pharmaceutical compositions of this invention is less than, or
equal to, about 2.0%, and preferably is less than, or equal to,
about 1.4% by weight when such compositions are stored at
25.degree. C. and about 60% relative humidity for extended time
periods, e.g., at least about 12 to about 18 months.
[0013] In another preferred embodiment, this invention provides a
bilayer solid composition comprising:
[0014] (a) an immediate release first layer comprising:
TABLE-US-00001 INGREDIENT mg/composition Desloratadine, micronized
2.5 Corn starch 11.0 Dibasic calcium phosphate dihydrate 53.0
Microcrystalline cellulose 30.22 Talc 3.0 FD&C Blue dye No. 2
Aluminium Lake 5627 0.28 TOTAL IN FIRST LAYER 100.00
and
[0015] (b) a second sustained release second layer comprising:
TABLE-US-00002 INGREDIENT mg/composition Pseudoephedrine Sulfate
120.0 Hydroxypropyl Methylcellulose 105.0 Microcrystalline
cellulose 100.0 Povidone 18.0 Silicon Dioxide 5.0 Magnesium
stearate 2.0 TOTAL IN SECOND LAYER 350.0
The total amount of desloratadine decomposition products such as
N-formyl-desloratadine (see Chart I) in the above-listed preferred
bilayer compositions is less than about 2.0% by weight when such
compositions are stored at 25.degree. C. and about 60% relative
humidity for extended time periods of at least about 15 to about 18
months.
[0016] In another preferred embodiment, the present invention also
provides a bilayer solid composition comprising (1) an immediate
release first layer comprising an anti-allergic effective amount of
desloratadine and a desloratadine-protective amount of at least one
pharmaceutically acceptable antioxidant; and (2) a sustained
release second layer comprising an effective amount of
pseudo-ephedrine or a pharmaceutically acceptable salt thereof, a
pharmaceutically acceptable sustained release agent, and a
desloratadine-protective amount of a pharmaceutically acceptable
antioxidant. The total amount of desloratadine decomposition
products such as N-formyldesloratadine (see Chart I) in the
above-listed preferred bilayer compositions is less than about 2.0%
by weight when such compositions are stored at 25.degree. C. and
about 60% relative humidity for extended time periods of at least
about 15 to about 18 months.
[0017] This invention further provides in another preferred
embodiment a bilayer solid composition comprising (a) an immediate
release first layer comprising an anti-allergic effective amount of
desloratadine and at least one pharmaceutically acceptable
excipient and (b) a sustained release second layer comprising an
effective amount of pseudoephedrine or a pharmaceutically
acceptable salt thereof and a pharmaceutically acceptable sustained
release agent and wherein the total amount of desloratadine
decomposition products in the bilayer solid composition is less
than about 2.0% by weight when such compositions are stored at
25.degree. C. and about 60% relative humidity for extended time
periods of at least about 15 to about 18 months.
[0018] In another preferred embodiment, the present invention also
provides a bilayer solid composition comprising (1) an immediate
release first layer comprising 5 mg of desloratadine and
desloratadine-protective amount of a pharmaceutically acceptable
water insoluble basic calcium, magnesium or aluminum salt, and (2)
a sustained release second layer comprising 120 mg of
pseudoephedrine sulfate, and a pharmaceutically acceptable
sustained release agent.
[0019] In another preferred embodiment, the present invention also
provides a bilayer solid composition comprising (1) a first layer
comprising 2.5 mg of desloratadine and a desloratadine-protective
amount of at least one pharmaceutically acceptable antioxidant; and
(2) a second layer comprising 120 mg of pseudoephedrine or a
pharmaceutically acceptable salt thereof, a pharmaceutically
acceptable excipient. Preferably there are two pharmaceutically
acceptable antioxidants in the first immediate layer.
[0020] In another preferred embodiment, the present invention also
provides a bilayer solid composition comprising (1) a first layer
comprising 5.0 mg of desloratadine and a desloratadine-protective
amount of at least one pharmaceutically acceptable antioxidant; and
(2) a second layer comprising 120 mg of pseudoephedrine or a
pharmaceutically acceptable salt thereof, a pharmaceutically
acceptable excipient. Preferably there are two pharmaceutically
acceptable antioxidants in the first immediate layer.
[0021] In another preferred embodiment, the present invention also
provides a solid composition comprising 2.5 mg of desloratadine and
a desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant. Preferably, there are two pharmaceutically
acceptable antioxidants in the solid compositions.
[0022] In another preferred embodiment, the present invention also
provides a solid composition comprising 2.5 mg of desloratadine and
a desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant. Preferably, there are two pharmaceutically
acceptable antioxidants in the solid composition.
[0023] We have also found that the total amount of desloratadine
decomposition products in the 2.5 mg and 5.0 mg solid compositions
is less than about 2.0%, and at least about 80% of the
desloratadine in the 2.5 mg and 5.0 mg solid compositions of the
present invention dissolves in 0.1N HCl at 37.degree. C. in about
45 minutes.
[0024] Thus, the present invention also provides a method of using
the solid compositions of the present invention for treating and/or
preventing allergic and inflammatory conditions of the upper and
lower airway passages and skin which comprises administering to a
patient in need of such treating an effective amount of a solid
composition of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0025] During the course of development of the compositions of the
present invention, desloratadine was found to be unstable and to
discolor when stored in combination with various excipients such as
those disclosed in U.S. Pat. No. 5,314,697 as part of the matrix
core containing pseudoephedrine sulfate. We have discovered two
solutions to minimize formation of desloratadine degradation
products. In one embodiment, we incorporate a desloratadine
protective amount of a pharmaceutically acceptable basic salt in
the immediate release layer containing desloratadine, and
substantially avoid the use of an acidic excipient in the immediate
release layer. In the second embodiment, we incorporate a
desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant in at least one layer and preferably we
incorporate two of said antioxidants into desloratadine-containing
immediate release layer.
[0026] In the bilayer solid compositions containing a
pharmaceutically acceptable water insoluble basic calcium,
magnesium or aluminum salt, we found that the excipients in the
immediate release layer causing discoloration and instability of
desloratadine include acidic excipients having a pH of less than 7
in water such as organic acids, such as stearic acid, povidone,
crospovidone as well as the hydroxycarboxylic acid, ascorbic acid,
and carbonyl-containing materials such as lactose, and
ethylcellulose and hydroxylpropyl methylcellulose. In this
preferred embodiment, we also discovered that it is possible to
prepare a bilayer tablet containing desloratadine in an immediate
release first layer in intimate contact with a sustained release
second layer containing a nasal decongestant and excipients
incompatible with desloratadine by incorporating a desloratadine
protective amount of a pharmaceutically acceptable water insoluble
basic calcium, magnesium or aluminum salt into the immediate
release desloratadine layer, and substantially avoiding the use of,
that is having less than about 0.1% by weight, prefabably less than
about 0.5%, and more prefabably less than about 0.25% of acidic
excipients in the immediate release layer.
[0027] Binders like povidone and polymers such as hydroxypropyl
methylcellulose are useful as a polymer matrix for the sustained
release of a pharmaceutically acceptable pseudoephedrine salt,
preferably pseudoephedrine sulfate, from the sustained release
layer.
[0028] We also discovered that metal ions catalyzed were involved
in the formation of desloratadine degradation products. In a
preferred embodiment, a desloratadine-protective amount of a
pharmaceutically acceptable anti-oxidant should be present in at
least one of the bilayers, preferably one of said antioxidant is
present in each layer, and more preferably two pharmaceutically
acceptable anti-oxidants are present in the desloratadine
layer.
[0029] The term "pharmaceutically acceptable antioxidant" as used
herein in reference to desloratadine ("DL", formula I in the Chart)
means a pharmaceutically acceptable chelating agent that protects
desloratadine from the formation of degradation products including,
but not limited to those of the formulas II-VII listed in the
Chart, e.g., N-formyl-desloratadine or N-formyl DL (formula II in
the Chart), N-hydroxylamine of DL (formula V in the Chart) N-oxide
of DL (formula IV in the Chart), and the 3'-hydroxyl N-oxide of DL
(formula III in the Chart), N-methyl DL (formula VI in the Chart),
and the ketone of formula VII. The structures listed in the Chart
were determined by standard physiochemical techniques, e.g., LC-MS,
and LC-NMR.
[0030] Typically suitable pharmaceutically acceptable antioxidants
for DL are pharmaceutically acceptable chelating agents such as
those disclosed in "Chelating Agents", pages 764-794, Vol. 5 of
KIRTH-OTHMER, ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY, 4.sup.th
Edition, 1993, John Wiley & Sons Inc., NY, and preferably
including, but not limited to, hydroxycarboxylic acids, such as
tartaric acid, citric acid and gluconic acid, and pharmaceutically
acceptable salts thereof, aminocarboxylic acids such as
iminodiacetic acid, N-methyliminodiacetic acid, nitrolotriacetic
acid, edetic acid (ethylenediamine tetraacetic acid),
diethylenetriaminepentaacetic acid,
1,2-diaminocyclohexanetetraacetic acid or
N-hydroxylethylenediaminetriacetic acid, and pharmaceutically
acceptable salts thereof such as the alkali and alkaline earth
salts, e.g., edetate calcium disodium, edetate disodium, edetate
trisodium, and edetate tetrasodium. Edetate disodium and citric
acid are the preferred pharmaceutically acceptable antioxidants.
Use of the hydroxycarboxylic acid, ascorbic acid, is to be
avoided
[0031] The desloratadine protective amount of a pharmaceutically
acceptable antioxidant in the desloratadine immediate release layer
is in the range of about 0.1% to about 10% by weight, preferably
about 1% to 8% or about 1% to about 6%, more preferably about 3% to
about 8%, or about 4% to about 6%, or most preferably about 5%. In
a preferred embodiment of this invention, two antioxidants are
present in the immediate release desloratadine layer, one
antioxidant, e.g., edeate disodium, in an amount of about 1% to
about 8%, preferably about 3% to about 8%, more preferably about 4%
to about 6%, or most preferably about 5%, and the second
antioxidant, e.g., citric acid, is present in an amount of about 1%
to about 8%, preferably about 3% to about 8%, more preferably about
4% to about 6%, or most preferably about 5%. The pharmaceutically
acceptable antioxidant in the pseudoephedrine sulfate ("PES")
sustained release layer is in the range of 0% to about 10%,
preferably about 0.1% to about 10%, or about 0.1% to about 3%, more
preferably about 1 to about 2%, and most more preferably about
1.0%. In a preferred embodiment of the present invention, about
1.0% by weight of a pharmaceutically acceptable antioxidant, e.g.,
edetate disodium, is present in the PES sustained release layer. In
another preferred embodiment, about 6% by weight of a mixture of
two pharmaceutically acceptable antioxidants, e.g., edetate
disodium and citric acid, are present in the DL immediate release
layer in a ratio of about 5:1 to about 1:5, preferably about 5:1,
and about 1% of a pharmaceutically acceptable antioxidant, e.g.,
edetate disodium, is present in the sustained release layer. In
another preferred embodiment, about 5% by weight of one
pharmaceutically acceptable antioxidant, e.g., edetate disodium, is
present in the desloratadine immediate release layer.
[0032] In other preferred embodiments, about 5.0 mg of
desloratadine is present in the immediate release layer, and 120 mg
of the nasal decongestant, pseudoephedrine sulfate, is present in
the sustained release layer (see Examples 4, 5 & 6). In one
preferred embodiment, the dibasic phosphate salt preferably dibasic
calcium phosphate dihydrate is present in the desloratadine
immediate release layer and no pharmaceutically acceptable
antioxidant is present in either layer (see Example 4). In another
preferred embodiment, 5.0 mg of desloratadine and about 0.1 to
about 10% of at least one antioxidant is present in the
desloratadine immediate release layer, preferably about 4% to about
6% of a mixture of two antioxidants, e.g., edetate disodium and
citric acid, in a ratio of 5:1 to 1:1, preferably in a ratio of
5:1, and about 0.1% to about 10% preferably about 0.1% to about 5%,
more preferably about 0.1% to about 3%, most more preferably about
1.0% of an antioxidant, e.g., edetate disodium, is present in the
PES sustained release layer (see Examples 5&6).
[0033] The desloratadine was found to have an acceptable immediate
release profile from the immediate release layer (80% release in
0.1N HCl in less than about 45 min.) and contain less than about 2%
of desloratadine degradation products even after storage for at
least 18 months at 25.degree. C. and about 60% relative humidity
("RH").
[0034] In another preferred embodiment, the present invention also
provides a solid composition comprising 2.5 mg of desloratadine and
a desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant. Preferably, there are two pharmaceutically
acceptable antioxidants in the solid compositions. See Example 9.
In another preferred embodiment, the present invention also
provides a solid composition comprising 5.0 mg of desloratadine and
a desloratadine-protective amount of at least one pharmaceutically
acceptable antioxidant. Preferably, there are two pharmaceutically
acceptable antioxidants in the solid composition. See for example,
Example 10. The desloratadine protective amount of a
pharmaceutically acceptable antioxidant in the 5.0 mg and 2.5 mg
solid compositions is in the range of about 0.1% to about 10% by
weight, preferably about 1% to 8% or about 1% to about 6%, more
preferably about 3% to about 8%, or about 4% to about 6%, or most
preferably about 5%. In a preferred embodiment of this invention,
two antioxidants are present in the 5.0 mg and 2.5 mg solid
compositions; one antioxidant, e.g., edeate disodium, in an amount
of about 1% to about 8%, preferably about 3% to about 8%, more
preferably about 4% to about 6%, or most preferably about 5%, and
the second antioxidant, e.g., citric acid, is present in an amount
of about 1% to about 8%, preferably about 3% to about 8%, more
preferably about 4% to about 6%, or most preferably about 5%. In
another preferred embodiment, about 6% by weight of a mixture of
two pharmaceutically acceptable antioxidants, e.g., edetate
disodium and citric acid, are present in the 5.0 mg and 2.5 mg
solid compositions in a ratio of about 5:1 to about 1:5, preferably
about 1:1. It has been surprisingly found that stearic acid could
be used in place of talc to overcome a tooling problem in the 5.0
mg and 2.5 mg solid compositions containing two pharmaceutically
acceptable antioxidants, e.g., edetate disodium and citric acid,
without adversely affecting the total amount of desloratadine
decomposition products.
[0035] We have found that the total amount of desloratadine
decomposition products in the 5.0 mg and 2.5 mg solid compositions
containing two pharmaceutically acceptable antioxidants, e.g.,
edetate disodium and citric acid, is less than about 2.0%, and
preferably about 1.5% by weight or less after storage at 25 c and
60% RH for extended time periods of at least 12 up to 15 months. In
addition, at least about 80% of the desloratadine in the 5.0 mg and
2.5 mg solid compositions containing two pharmaceutically
acceptable antioxidants, e.g., edetate disodium and citric acid,
dissolves in 0.1N HCl at 37.degree. C. in about 45 minutes.
[0036] In another preferred embodiment, a desloratadine-protective
amount of a pharmaceutically acceptable anti-oxidant should be
present in at least one of the bilayers, preferably one of said
antioxidant in each layer.
[0037] The two layers of the bilayer tablets of this invention may
be in intimate contact with one another, or have a layer at the
interfaces of the two layers. The layer at the interfaces of the
two layers may be a water-swellable film-forming polymer containing
one or more pharmaceutically acceptable excipients or the layer may
also contain at least one pharmaceutically acceptable
antioxidant.
[0038] The term "in intimate contact" as used herein in reference
to the two layers forming the bilayer tablet means that there is
with no film interface between the two layers.
[0039] The term "water-swellable film-forming neutral or cationic
copolymeric ester," as used herein means neutral and cationic
copolymers of ethyl acrylate and substituted unsubstituted methyl
or ethyl methacrylate esters.
[0040] Typically suitable water swellable film-forming neutral
copolymeric esters include neutral copolymers of ethyl acrylate and
methyl metharylate such as are available from Pharma Poloymers, a
company of the Huls Group under the EUDRAGIT.RTM. Tradename;
EUDRAGIT NE30D. and Kollicoat available from BASF, Mt Olive, N.J.
An aqueous dispersion containing 30% by weight of a neutral
copolymer based on ethyl crylate and methyl methoacrylate (average
molecular weight of approximately 800,000) is preferred.
[0041] Typically suitable water-swellable film-forming cationic
co-polymeric esters include cationic co-polymerers based on
dimethylaminoethylmethacrylate and a neutral methacrylic ester such
as the EUDRAGIT E copolymers available from Pharma Polymers as a
12.5% solution (EUDRAGIT E 12.5) or as solid (EUDRAGIT E 100) and
quaternay ammonium copolymers described in USP/NF as "Amononio
methacrylate copolymer, Type A" and Type "B". Such copolymers are
available as aqueous dispersions of copolymers of acrylic and
methacrylic acid esters with a low (substitution) content of
quaternary ammonium groups present as salts, (e.g., quaternary
ammonium chlorides). Type A and Type B are available as 30% aqueous
dispersions under the EUDRAGIT RL 30D and EUDRAGIT RS 30D
tradenames, respectively. Use of the water-swellable film--from
neutral co-polymeric esters based on ethyl acrylate and
methacrylate is preferred.
[0042] The term "water soluble film modifier" as used herein means
a film-forming agent which modifies the water-swellable
characteristics of the film-forming neutral or cationic copolymeric
esters useful in the layer at the interface of the bilayer
compositions of the present invention. A typically suitable water
soluble film-modifying agent is a low viscosity (.ltoreq.20 cps)
cellulose such as low viscosity hydroxypropyl methyl cellulose, low
viscosity hydroxylethyl methyl cellulose; low viscosity sodium
carboxymethyl cellulose or a polyethylene glycol selected from
polyethylene glycol 200 to polyethylene glycol 8000.
[0043] Use of a polyethylene glycol 6000 to polyethylene glycol
8000 as a film modifier is preferred.
[0044] The phrase "allergic and inflammatory conditions of the skin
and airway passages" means those allergic and inflammatory
conditions and symptoms found on the skin and in the upper and
lower airway passages from the nose to the lungs. Typical allergic
and inflammatory conditions of the skin and upper and lower airway
passages include seasonal and perennial allergic rhinitis,
non-allergic rhinitis, asthma including allergic and non-allergic
asthma, sinusitis, colds (in combination with a NSAID, e.g.,
aspirin ibuprofen or APAP) and/or a decongestant e.g.
pseudoephedrine), dermatitis, especially allergic and atopic
dermatitis, and urticaria and symptomatic dermographism as well as
retinophathy, and small vessel diseases, associated with diabetes
mellitus.
[0045] The amount of desloratadine effective for treating or
preventing allergic and inflammatory conditions of the skin and
upper and lower airway passages will vary with the age, sex, body
weight and severity of the allergic and inflammatory condition of
the patient. Typically, the amount of desloratadine effective for
treating or preventing such allergic and inflammatory conditions is
in the range of about 2.5 mg/day to about 60 mg/day, preferably
about 2.5 mg/day to about 20 mg/day, or about 4.0 mg/day to about
15 mg/day, or about 5.0 mg/day to about 10 mg/day, more preferably
about 5.0 mg/day to about 10.0 mg/day, and most preferably about
5.0 mg/day in one dose or in two divided doses of 2.5 mg/dose.
[0046] Desloratadine is a non-sedating long acting histamine
antagonist with potent selective peripheral H1-receptor antagonist
activity. Following oral administration, loratadine is rapidly
metabolized to descarboethoxyloratadie or desloratadine, a
pharmacologically active metabolite. In vitro and in vivo animal
pharmacology studies have been conducted to assess various
pharmacodynamic effects of desloratadine and loratadine. In
assessing antihistamine activity in mice (comparison of ED.sub.50
value), desloratadine was relatively free of producing alterations
in behavior alterations in behavior, neurologic or autonomic
function. The potential for desloratadine or loratadine to occupy
brain H1-receptors was assessed in guinea pigs following i.p.
administration and results suggest poor access to central histamine
receptors for desloratadine or loratadine.
[0047] In addition to antihistaminic activity, desloratadine has
demonstrated anti-allergic and anti-inflammatory activity from
numerous in vitro and in vivo tests. These in vitro tests (mainly
conducted on cells of human origin) have shown that desloratadine
can inhibit many events in the cascade of allergic inflammation.
These anti-inflammatory effects for desloratadine are independent
of the H1-antagonist effect of desloratadine and include: [0048]
The release of inflammatory mediators histamine, truptase,
leukotriene and prostaglandin D2 from mast cells; [0049] The
release of inflammatory cytokines including IL-4, IL-6, IL-8 and
IL-13; [0050] The release of the inflammatory chemokines such as
RANTES (regulated upon activation, normal T cell expressed and
presumably secreted); [0051] Superoxide anion production of
polymorphonuclear-neutrophils; [0052] The expression of cell
adhesion molecules such as intracellular adhesion molecules
(ICAM-1) and P-selection in endothelial cells; and [0053]
Eosinophil migration and adhesion In vivo studies also suggest that
an inhibitory effect of desloratadine on allergic bronchospasm and
cough can also be expected.
[0054] The clinical efficacy and safety of desloratadine has been
documented in over 3,200 seasonal allergic rhinitis patients in 4
double-blind, randomized clinical trials. The results of these
chemical studies demonstrated the efficacy of desloratadine in the
treatment of adult and adolescent patients with seasonal
rhinitis.
[0055] The nasal decongestants useful in the present invention
include phenylpropanolamine, phenylephrine and pseudoephedrine.
Pseudoephedrine as well as pharmaceutically acceptable acid
additional salts, e.g., those of HCl or H.sub.2SO.sub.4, is a
sympathomimetic drug recognized by those skilled in the art as a
safe therapeutic agent effective for treating nasal congestion and
is commonly administered orally and concomitantly with an
antihistamine for treatment of nasal congestion associated with
allergic rhinitis. The use of pseudoephedrine as a nasal
decongestant in the present invention is preferred; the use of
about 120 mg pseudoephedrine sulfate in the extended release layer
is more preferred. However, lesser amounts of pseudoephedrine
sulfate may be used in combination with desloratadine, e.g., in
combination with the 2.5 and 5.0 solid compositions of the present
invention such as described in Examples 9 and 10.
[0056] In the course of development of the compressed bilayer oral
dosage composition of this invention, it was discovered that the
selection of the polymers for the extended release layer was
critical to achieve the desired extended release period of at least
12 hours, for pseudoephedrine sulfate. For example, the use of
hydroxypropyl methylcellulose 4,000 cps or 15,000 cps as polymers
in the matrix core did not provide this more preferred extended
release period of at least 16 hours for dose of pseudoephedrine
sulfate. We discovered that only by selecting for inclusion into
the matrix core of specific weight ratios of three specific
polymers was the desired pseudoephedrine release profile achieved.
Only by combining (1) about one part by weight, preferably 1.05
parts by weight of hydroxypropyl methylcellulose 2208 USP, 100,000
cps with (2) about one part by weight, preferably 1.0 parts by
weight of microcrystalline cyellulose together with (3) about
0.15-0.20 part by weight., preferably 0.17-0.18 parts by weight of
povidone (per 1.05 parts by weight of hydroxypropyl
methylcellulose) as a secondary binder was the more preferred
extended release profile of at least 12 hours for pseudoephedrine
sulfate from the extended release layer. The extended release layer
also contains specific amounts of silicon dioxide as a glidant and
magnesium stearate as a lubricant. The tablet hardness 20.+-.4
Strong-Cobb Units (SCU) is not greatly affected by the higher level
of lubricant (6 mg/tablet) but it is preferred to maintain the
lubricant level at 1/9 part by weight of lubricant to one part by
weight of povidone as secondary binder.
[0057] The term "lubricant` as used herein refers to a substance
added to the dosage form to enable the dosage form, e.g., a tablet,
after it has been compressed to release from the mold or die.
[0058] Suitable lubricants include talc, magnesium stearate,
calcium stearate, stearic acid, hydrogenated vegetable oils and the
like. Preferably, magnesium stearate or talc is used.
[0059] The term "glidants" as used herein refers to a substance,
such as an anti-caking agent, which improves the flow
characteristics of a powder mixture.
[0060] Suitable glidants include silicon dioxide and talc.
Preferably, silicon dioxide is used.
[0061] The term "binders" as used herein means any material that is
added to pharmaceutical compositions to help hold such compositions
together and release the medicament therefrom.
[0062] Suitable binders are selected those found in NF XVIII, page
2206 (1995) and include povidones, starches, celluloses, alginates,
and gums and low molecular weight hydroxypropyl melthyl celluloses,
especially hydroypropyl methyl celluose 2910.
[0063] The term "pharmaceutically acceptable water insoluble basic
calcium, magnesium and aluminium salts" as used herein means the
pharmaceutically acceptable carbonates, phosphates, silicates and
sulfates of calcium, magnesium and aluminum or mixtures thereof.
Typically suitable pharmaceutically acceptable basic salts include
calcium sulfate anhydrous, hydrates of calcium sulfate, such as
calcium sulfate dihydrate, magnesium sulfate anhydrous, hydrates of
magnesium sulfate, dibasic calcium phosphate, dibasic calcium
silicate, magnesium trisilicate, magnesium phosphate, aluminum
silicate, and hydrates of magnesium phosphate, aluminum phosphate;
and calcium phosphate is more preferred. The use of dibasic calcium
phosphate dihydrate is most preferred.
[0064] The desloratadine-protective amount of a pharmaceutically
acceptable water insoluble basic calcium, magnesium or aluminum
salt is in the range of about 50-60% of the DL immediate release
layer, and the w/w ratio of the pharmaceutically acceptable water
insoluble basic calcium, magnesium or aluminum salt to DL is in the
range of about 8:1 to about 40:1, more preferably is in the range
of about 10:1 to about 20:1, and most preferably is in the range of
about 10:1 to about 11:1.
[0065] In the preferred embodiment of the present invention wherein
a desloratadine protective amount of a pharmaceutically acceptable
antioxidant is present, the water insoluble basic calcium salt is
not present in the immediate release layer containing
desloratadine; in its place, at least one, preferably two
pharmaceutically acceptable antioxidants are present, e.g., edetate
sodium and citric acid and the amount of microcrystalline cellulose
is increased. In addition, when the pharmaceutically acceptable
antioxidant is used in place of the water insoluble basic calcium,
magnesium or aluminum salt, the povidone in the sustained release
layer is replaced by another binder, preferably a low molecular
weight hydroxypropyl methyl cellulose ("HPMC"), preferably HPMC
2910.
[0066] In the preparation of the bilayer tablet, the sustained
release layer is compacted first. The immediate release second
layer is added on top and a compression force sufficient to form a
bilayer tablet is applied in the range of 8-12 kilo Newtons,
preferably about 9 kilo Newtons (kN).
[0067] The dried sustained release granulation is milled and
blended with requisite amounts of silicon dioxide and magnesium
stearate. In a preferred embodiment, a pharmaceutically acceptable
blue dye containing EDTA as a chelating agent is incorporated into
the immediate release desloratadine layer. Use of a
pharmaceutically acceptable blue dye, e.g. FD& C blue dye No. 2
Aluminum Lake 5627 is preferred.
Example 1
[0068] This example illustrates preparation of the preferred oral
dosage composition of this invention. The ingredients and specific
amounts thereof are listed below.
[0069] A. Method of Manufacture of the Immediate Release Layer
[0070] 1. Prepare starch paste by dispersing the paste portion of
corn starch into purified water in a suitable container equipped
with an agitator. [0071] 2. While mixing, heat the contents to
approximately 95.degree. C. and maintain the temperature for
approximately 30 minutes. [0072] 3. After Step 2 is completed, add
an additional purified water and allow the starch paste to cool to
approximately 50.degree. C. [0073] 4. While mixing, add
desloratadine to the starch paste. Continue mixing during the
granulation step. [0074] 5. Pass the FD&C blue No. 2 aluminum
lake containing EDTA as a chelating,e.g., Spectra Spray Med Blue,
with the required amount of dibasic calcium phosphate through a
suitable sieve or mill. [0075] 6. Charge to a suitable fluid bed
processing bowl the remaining dibasic calcium phosphate dihydrate,
the milled material from Step 5, a portion of the corn starch, and
a portion of microcrystalline cellulose. Place the processing bowl
into the fluid bed processor. [0076] 7. Fluidize the powder bed
until the product temperature reaches approximately 29.degree. C.
[0077] 8. Begin granulating the powder by pumping the starch paste
from Step 4 into the fluidized bed at a suitable spray rate and a
bed temperature of approximately 22.degree. C. [0078] 9. Continue
to dry the granulation at an inlet air temperature of approximately
60.degree. C. until a final loss on drying (LOD) of 2% or less is
achieved. [0079] 10. Pass the dried granulation through a suitable
sieve or mill. [0080] 11. Charge the granulation to a suitable
blender and add the requisite amounts of the remaining portion of
microcrystalline cellulose, corn starch, and talc. Blend for 5
minutes.
[0081] B. Manufacture of Sustained Release Mix: [0082] 1. Charge
purified water and alcohol to a suitable container equipped with an
agitator. [0083] 2. Dissolve povidone in the water/alcohol mixture.
Continue mixing for a minimum of 10 minutes. [0084] 3. Mix
hydroxypropyl methylcellulose, pseudoephedrine sulfate and
microcrystalline cellulose in a suitable granulator. [0085] 4.
Granulate the mix with the povidone solution, using additional
water/alcohol mixture if necessary to achieve the appropriate
granulation consistency. [0086] 5. Dry the wet granulation at
approximately 50.degree. C. in a suitable dryer until the loss on
drying (LOD) is between 1% and 3%. [0087] 6. Pass the dried
granulation through a suitable sieve or mill. [0088] 7. Charge the
milled granulation to a suitable blender. [0089] 8. Pass the
silicon dioxide through a No. 30 mesh screen into the blender.
[0090] 9. Blend the requisite amount of screened silicon dioxide
with the granulation for approximately 10 minutes in a suitable
blender. [0091] 10. Pass the magnesium stearate through a No. 30
mesh screen. [0092] 11. Blend the requisite amount of screened
magnesium stearate with the mix from Step 9 for 5 minutes.
[0093] C. Compression: [0094] Compress the two blends to
specifications as bilayer tablets using a suitable double-layer
tablet press using a compression force of 9 k Newtons. Compress the
sustained release layer first. [0095] Tablet Weight: 450 mg.+-.5%
[0096] Sustained release layer: 350 mg.+-.5% [0097] Immediate
release layer 100 mg.+-.5% [0098] Hardness: 20.+-.4 SCU (Strong
Cobb units) [0099] The following bilayer tablet was prepared using
the above procedure.
[0100] Desloratadine Immediate Release Layer:
TABLE-US-00003 INGREDIENT mg/composition Desloratadine, micronized
2.5 Corn Starch NF/Ph. Eur. 11.0 Dibasic Calcium Phosphate
Dihydrate USP/Ph. Eur. 53.0 Microcrystalline Cellulose NF/Ph.
Eur./JP 30.22 Talc USP/Ph. Eur. 3.0 Dye FD&C Blue No. 2
Aluminium Lake 5627 0.28 Water Purified USP/Ph. Eur. -- TOTAL
100.00
and
[0101] Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00004 INGREDIENT mg/composition Pseudoephedrine Sulfate
USP 120.0 Hydroxypropyl Methylcellulose 2208, USP, 105.0 100,000
cps (K100M)/Ph. Eur. Microcrystalline Cellulose NF/Ph. Eur./JP
100.0 Povidone USP/Ph. Eur./JP 18.0 Silicon Dioxide NF 5.0
Magnesium Stearate NF/Ph. Eur. JP(Non-Bovine) 2.0 Water Purified
USP/Ph. Eur. -- Alcohol USP/3A Alcohol -- TOTAL 350.0 TOTAL TABLET
450.0
[0102] Hardness: 20.+-.4 SCU (Strong Cobb units)
Example 2
[0103] The procedure of Example 1 was used; edetate disodium was
used in place of the dibasic calcium salt and the amount of
microcrystalline cellulose in the DL layer was increased. Edetate
disodium was used in the sustained release layer and hydroxypropyl
methylcellulose 2910 was used in place of povidone.
Desloratadine Immediate Release Layer:
TABLE-US-00005 [0104] INGREDIENT mg/composition Desloratadine,
micronized 2.5 Corn Starch NF/Ph. Eur. 8.0 Microcrystalline
Cellulose NF/Ph. Eur./JP 71.35 Edetate Disodium 5.0 Talc USP/Ph.
Eur. 3.0 Dye FD&C Blue No. 2 Aluminium Lake 5627 0.15 Water
Purified USP/Ph. Eur. -- TOTAL 100.00
and
[0105] Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00006 INGREDIENT mg/composition Pseudoephedrine Sulfate
USP 120.0 Hydroxypropyl Methylcellulose 2208, USP/Ph. Eur. 105.0
Microcrystalline Cellulose NF/Ph. Eur./JP 103.5 Edetate Disodium
3.5 Hydroxypropyl Methylcellulose 2910 USP/Ph. Eur./JP 10.5 Silicon
Dioxide NF 5.0 Magnesium Stearate NF/Ph. Eur. JP(Non-Bovine) 2.5
Water Purified USP/Ph. Eur. -- Alcohol USP/3A Alcohol -- TOTAL
350.0 TOTAL TABLET 450.0
[0106] Hardness: 20.+-.4 SCU (Strong Cobb units)
Example 3
[0107] The procedure of Example 2 was used, but 1 mg of citric acid
was added to the DL layer and the amount of microcrystalline
cellulose was decreased by 1 mg.
Desloratadine Immediate Release Layer:
TABLE-US-00007 [0108] INGREDIENT mg/composition Desloratadine,
micronized 2.5 Corn Starch NF/Ph. Eur. 18.0 Edetate Disodium 5.0
Citric Acid 1.0 Microcrystalline Cellulose NF/Ph. Eur./JP 70.35
Talc USP/Ph. Eur. 3.0 Dye FD&C Blue No. 2 Aluminium Lake 5627
0.15 Water Purified USP/Ph. Eur. -- TOTAL 100.00
And Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00008 [0109] INGREDIENT mg/composition Pseudoephedrine
Sulfate USP 120.0 Hydroxypropyl Methylcellulose 2208, 100,000 cps
105.0 (K100M)USP/Ph. Eur. Microcrystalline Cellulose NF/Ph. Eur./JP
103.5 Edetate Disodium 3.5 Hydroxypropyl Methylcellulose 2910 10.5
Silicon Dioxide NF 5.0 Magnesium Stearate NF/Ph. Eur.
JP(Non-Bovine) 2.5 Water Purified USP/Ph. Eur. -- Alcohol USP/3A
Alcohol -- TOTAL 350.0 TOTAL TABLET 450.0
[0110] Hardness: 20.+-.4 SCU (Strong Cobb units)
Example 4
[0111] The procedure of Example 1 was used. The bilayer tablet of
Example 1 was modified by including 5.0 mg of desloratadine in the
immediate release layer--(a 24 hour dose)--with the appropriate
changes in amounts of the other ingredients and using the 12-hr
dose pseudoephedrine sustained release layer of Example 1.
Hardness: 20.+-.4 SCU (Strong Cobb units)
Desloratadine Immediate Release Layer:
TABLE-US-00009 [0112] INGREDIENT mg/composition Desloratadine,
micronized 5.0 Corn Starch NF/Ph. Eur. 11.0 Dibasic Calcium
Phosphate Dihydrate USP/Ph. Eur. 53.0 Microcrystalline Cellulose
NF/Ph. Eur./JP 27.72 Talc USP/Ph. Eur. 3.0 Dye FD&C Blue No. 2
Aluminium Lake 5627 0.28 Water Purified USP/Ph. Eur. -- TOTAL
100.00
and
[0113] Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00010 INGREDIENT mg/composition Pseudoephedrine Sulfate
USP 120.0 Hydroxypropyl Methylcellulose 2208, 1000,00 cps 105.0
(K100M)USP/Ph. Eur. Microcrystalline Cellulose NF/Ph. Eur./JP 100.0
Povidone USP/Ph. Eur./JP 18.0 Silicon Dioxide NF 5.0 Magnesium
Stearate NF/Ph. Eur. JP(Non-Bovine) 2.0 Water Purified USP/Ph. Eur.
-- Alcohol USP/3A Alcohol -- TOTAL 350.0 TOTAL TABLET 450.0
Example 5
[0114] The procedure of Example 1 was used and the bilayer tablet
of Example 4 was modified by replacing the dibasic calcium
phosphate dihydrate in the immediate release layer with 10 mg of
edetate disodium and increasing the amount of microcrystalline
cellulose by 2.7 mg. Hardness: 20.+-.4 SCU (Strong Cobb units)
Desloratadine Immediate Release Layer:
TABLE-US-00011 [0115] INGREDIENT mg/composition Desloratadine,
micronized 5.0 Corn Starch NF/Ph. Eur. 36.0 Microcrystalline
Cellulose NF/Ph. Eur./JP 142.7 Edetate Disodium 10.0 Talc USP/Ph.
Eur. 6.0 Dye FD&C Blue No. 2 Aluminium Lake 5627 0.30 Water
Purified USP/Ph. Eur. -- TOTAL 200.00
and
[0116] Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00012 INGREDIENT mg/composition Pseudoephedrine Sulfate
USP 120.0 Hydroxypropyl Methylcellulose 2208, 1000,00 cps 105.0
USP/Ph. Eur. Microcrystalline Cellulose NF/Ph. Eur./JP 103.5
Hydroxypropyl Methylcellulose 2910 10.5 Edetate Disodium 3.5
Silicon Dioxide NF 5.0 Magnesium Stearate NF/Ph. Eur.
JP(Non-Bovine) 2.5 Water Purified USP/Ph. Eur. -- Alcohol USP/3A
Alcohol -- TOTAL 350.0 TOTAL Tablet Weight 550.0
Example 6
[0117] The bilayer tablet of Example 5 was modified by adding 2.0
mg of citric acid to the immediate release layer and decreasing the
amount of microcrystalline cellulose by 2.7 mg and using the
pseudoephedrine sustained release layer of Example 1. Hardness:
20.+-.4 SCU (Strong Cobb units)
Desloratadine Immediate Release Layer:
TABLE-US-00013 [0118] INGREDIENT mg/composition Desloratadine,
micronized 5.0 Corn Starch NF/Ph. Eur. 36.0 Microcrystalline
Cellulose NF/Ph. Eur./JP 140.7 Edetate Disodium 10.0 Citric Acid
2.0 Talc USP/Ph. Eur. 6.0 Dye FD&C Blue No. 2 Aluminium Lake
5627 0.30 Water Purified USP/Ph. Eur. -- TOTAL 200.00
And Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00014 [0119] INGREDIENT mg/composition Pseudoephedrine
Sulfate USP 120.0 Hydroxypropyl Methylcellulose 2208, 1000,00 cps
105.0 USP/Ph. Eur. Microcrystalline Cellulose NF/Ph. Eur./JP 103.5
Hydroxypropyl Methylcellulose 2910 10.5 Edetate Disodium 3.5
Silicon Dioxide NF 5.0 Magnesium Stearate NF/Ph. Eur.
JP(Non-Bovine) 2.5 Water Purified USP/Ph. Eur. -- Alcohol USP/3A
Alcohol -- TOTAL 350.0 TOTAL Tablet Weight 550.0
Example 7
[0120] The bilayer tablet of Example 5 was modified by replacing
the talc with an equivalent weight of stearic acid, and by adding
an additional 8.0 mg of citric acid to the immediate release layer
and decreasing the amount of microcrystalline cellulose by 8.0 mg
and replacing 4.0 g of the microcrystalline cellulose and all of
the hydroxypropyl methylcellulose and edetate disodium with 18.0 g
of popovidone the pseudoephedrine in the sustained release layer of
Example 6.
Desloratadine Immediate Release Layer:
TABLE-US-00015 [0121] INGREDIENT mg/composition Desloratadine,
micronized 5.0 Corn Starch NF/Ph. Eur. 36.0 Microcrystalline
Cellulose NF/Ph. Eur./JP 132.7 Edetate Disodium USP 10.0 Citric
Acid Anhydrous, USP 10.0 Stearic Acid, NF. 6.0 Dye FD&C Blue
No. 2 Aluminium Lake 5627 0.30 Water Purified USP/Ph. Eur. -- TOTAL
200.00
And Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00016 [0122] INGREDIENT mg/composition Pseudoephedrine
Sulfate USP 120.0 Hydroxypropyl Methylcellulose 2208, 1000,00 cps
105.0 USP/Ph. Eur(K100M). Microcrystalline Cellulose NF/Ph. Eur./JP
99.5 Povidone, USP 18.0 Silicon Dioxide NF 5.0 Magnesium Stearate
NF/Ph. Eur. JP(Non-Bovine) 2.5 Water Purified USP/Ph. Eur. --
Alcohol USP/3A Alcohol -- TOTAL 350.0 TOTAL Tablet Weight 550.0
Example 8
[0123] The bilayer tablet of Example 7 was modified by decreasing
the weight of all ingredients in the desloratadine immediate
release layer by 50% and using the sustained release layer of
Example 7
Desloratadine Immediate Release Layer:
TABLE-US-00017 [0124] INGREDIENT mg/composition Desloratadine,
micronized 2.5 Corn Starch NF/Ph. Eur. 18.0 Microcrystalline
Cellulose NF/Ph. Eur./JP 66.35 Edetate Disodium USP 5.0 Citric Acid
Anhydrous, USP 5.0 Stearic Acid, NF. 3.0 Dye FD&C Blue No. 2
Aluminium Lake 5627 0.15 Water Purified USP/Ph. Eur. -- TOTAL
100.00
And Pseudoephedrine Sulfate Sustained Release Layer
TABLE-US-00018 [0125] INGREDIENT mg/composition Pseudoephedrine
Sulfate USP 120.0 Hydroxypropyl Methylcellulose 2208, 1000,00 cps
105.0 USP/Ph. Eur(K100M). Microcrystalline Cellulose NF/Ph. Eur./JP
99.5 Povidone, USP 18.0 Silicon Dioxide NF 5.0 Magnesium Stearate
NF/Ph. Eur. JP(Non-Bovine) 2.5 Water Purified USP/Ph. Eur. --
Alcohol USP/3A Alcohol -- TOTAL 350.0 TOTAL Tablet Weight 450.0
Example 9
[0126] A desloratadine (2.5 mg) tablet was prepared by using the
desloratadine immediate release layer of Example 8.
TABLE-US-00019 INGREDIENT mg/composition Desloratadine, micronized
2.5 Corn Starch NF/Ph. Eur. 18.0 Microcrystalline Cellulose NF/Ph.
Eur./JP 66.35 Edetate Disodium USP 5.0 Citric Acid Anhydrous, USP
5.0 Stearic Acid, NF. 3.0 Dye FD&C Blue No. 2 Aluminium Lake
5627 0.15 Water Purified USP/Ph. Eur. -- TOTAL Tablet Weight
100.00
Example 10
[0127] A desloratadine (5.0 mg) tablet was prepared by using the
desloratadine immediate release layer of Example 7.
TABLE-US-00020 INGREDIENT mg/composition Desloratadine, micronized
5.0 Corn Starch NF/Ph. Eur. 36.0 Microcrystalline Cellulose NF/Ph.
Eur./JP 132.7 Edetate Disodium USP 10.0 Citric Acid Anhydrous, USP
10.0 Stearic Acid, NF. 6.0 Dye FD&C Blue No. 2 Aluminium Lake
5627 0.30 Water Purified USP/Ph. Eur. -- TOTAL TABLET WEIGHT
200.00
[0128] The in vitro dissolution profile of the tablets of Examples
1-10 were measured in a stirred 0.1N HCl solution at 37.degree. C.
(1.sup.st hour) and thereafter in a stirred phosphate buffer having
a pH of 7.5 at 37.degree. C. The 80% of desloratadine in the
immediate release layers was dissolved within the first 30 minutes
and the total dose of pseudoephedrine sulfate in the sustained
release layers of Examples 1-8 was slowly released via erosion and
dissolution mechanisms over a period of at least 12 hours. (with
30-45% in 1 hr, 50-605% in 2 hrs. and .gtoreq.80% in 6 hrs).
[0129] Similar results would be expected if a decongestant
effective amount of another pharmaceutically acceptable
pseudoephedrine salt, e.g., pseudoephedrine hydrochloride was used
in place of pseudoephedrine sulfate.
[0130] The compositions of the present invention are useful for
treatment of allergic and/or inflammatory conditions of the skin
(e.g. urticaria) and the upper and lower airway passages including
the nasal and non-nasal symptoms of perennial and seasonal allergic
rhinitis including nasal congestion in a patient in need of such
treating. The precise dosage and dosage regimen may be varied by
the attending clinician in view of the teachings herein depending
upon the requirements of the patient, e.g., the patients age, sex
and the severity of the allergic and/or inflammatory condition
being treated. Determination of the proper dosage and dosage
regimen for a particular patient will be within the skill of the
attending clinician. While we have hereinabove presented a number
of preferred embodiments of this invention by way of example, it is
apparent that the scope of the invention is to be defined by the
scope of the appended claims.
##STR00001## ##STR00002##
* * * * *